Displaying drugs 14976 - 15000 of 15713 in total
Yttrium Y-90 Labetuzumab
Investigational
BHT-3034
BHT-3034 is a DNA plasmid vaccine immunotherapy under investigation for the treatment of myasthenia gravis.
Investigational
SIS-101-ADO
SIS-101-ADO is a siRNA therapeutic under investigation for the treatment of Autosomal Dominant Osteopetrosis Type 2 (ADO2).
Investigational
PBKR03
PBKR03 is a non-replicating recombinant adeno-associated virus serotype hu68 vector, containing a transgene encoding the human galactosylceramidase (GALC) enzyme.
Investigational
ATX-01
ATX-01 is an antimiR, a chemically modified antisense oligonucleotide, designed to target microRNA 23b (miR-23b).
Investigational
Zilganersen
Investigational
ION283
Investigational
LipidRescue
Investigational
LYT-200
LYT-200 is a fully human IgG4 monoclonal antibody directed against galectin-9.
Investigational
OM-301
Investigational
ACT-1 peptide
Investigational
FCX-013
FCX-013 consists of human dermal fibroblasts genetically modified with a lentiviral vector expressing metalloproteinase-1 (MMP-1).
Investigational
INO-3107
Investigational
KB105
Investigational
AMP-101
AMP-101 is a gene therapy comprising an adeno-associated virus type 9 (AAV9) vector encoding the human Dok-7 protein. It is under investigation for the treatment of Dok-7-associated myasthenia.
Investigational
VGM-R02b
Investigational
EXOB-001
EXOB-001 consists of extracellular vesicles derived from cultured human umbilical cord mesenchymal stromal cells.
Investigational
VTX-803
Investigational
LX-1004
Investigational
OCU400
OCU400 is a novel gene therapy comprising an adeno-associated viral vector expressing human nuclear hormone receptor subfamily 2 group E member 3 (hNR2E3).
Investigational
DB-OTO
Investigational
UX701
Investigational
AXV101
Investigational
Displaying drugs 14976 - 15000 of 15713 in total